pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MRNAModerna, Inc.

$MRNA214.16+2.98%
Cambridge, MA, USupdated 23d ago

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
18
marketed
5
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(18)

view full pipeline →
pipeline depth18 products
Phase 1: 5Phase 2: 5Phase 3: 1Marketed: 5pre_registration: 2
5Phase 15Phase 21Phase 35Marketed2pre_registration
Marketed
Coronavirus Disease 2019 (COVID-19) KP.2 vaccine
Coronavirus Disease 2019 (COVID-19)
Marketed
Coronavirus Disease 2019 (SARS-CoV-2) vaccine 2
Coronavirus Disease 2019 (COVID-19)
Marketed
davesomeran + elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
mNEXSPIKE
Coronavirus Disease 2019 (COVID-19)
Phase 3
mRNA-1403
Norovirus Infections
Phase 2
intismeran autogene
Metastatic Melanoma
Phase 2
mRNA-3705
Methylmalonic Acidemia
Phase 2
mRNA-3927
Propionic Acidemia
Phase 2
mRNA-4359
Solid Tumor
Phase 2
respiratory syncytial virus vaccine
Respiratory Syncytial Virus (RSV) Infections
Fusion glycoprotein F0
Phase 1
mRNA-1215
Nipah Virus (NiV) Infections

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Wall Street consensus

source: yahoo finance · 20 analysts
mean target
$46.10
vs $49.56 now
implied upside
-7.0%
range: $21.00 – $135.00
consensus rating
Hold
2.96 / 5.0
rating distribution · 23 analysts
1
2
17
1
2
strong buystrong sell
🐶 Hiring Signal
237 open roles at Moderna, Inc. →

Where Moderna, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 17Infectious Disease & Vaccines 10Immunology & Inflammation 4CNS / Neuroscience 2Rare Disease 1
departmentIT & Engineering 42Manufacturing / CMC 35Quality 32R&D / Discovery 22Regulatory 12Commercial 11

News

  • As part of sales reorganization, Novo will cut 215 employees at US HQ
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 14h ago
  • FDA’s search for a new leader, and China’s largest drugmakers
    This week on "The Readout LOUD" podcast: the FDA is again searching for a new leader and a closely tracked lung cancer drug suffers an agency rejection.
    stat · 20h ago
  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
    Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
    biospace · 2d ago
  • Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
    Pfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.
    fiercebiotech · 2d ago
  • Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease
    For some rare genetic diseases, the problem isn't a missing protein but the buildup of toxic molecules that the body can no longer clear away.
    fiercebiotech · 3d ago
  • The future of heart drug research in the wake of study setbacks
    What does the failure of two closely watched heart disease medicines mean for the future of drug research in the field? Find out on this week's episode of "The Readout…
    stat · 7d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 11d ago
  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 13d ago
  • Democrats’ midterm victory, and a questionable fertility procedure
    How will the midterm results affect drug pricing policy? And why are women traveling to fertility clinics abroad? Find out on the new episode of "The Readout LOUD" podcast.
    stat · 14d ago
  • Moderna enjoys stable vaccine sales thanks to global COVID uptake
    While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.
    biospace · 14d ago
view all news mentions →
identifiers
ticker
$MRNA
SEC CIK
0001682852
country
US
source
sec_tickers
top tags
Infectious Disease13Oncology3Colorectal Cancer1NSCLC1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?